文献速递炎症性肠病

托法替布延长诱导治疗溃疡性结肠炎的疗效与安全性

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-27

在初始8周托法替布10 mg每日两次诱导未达临床缓解的溃疡性结肠炎患者中,延长诱导至16周后52.2%达到临床应答(延迟应答者)。OCTAVE Open第12个月时,70.3%维持临床应答、56.8%达到内镜改善、44.6%达到缓解;第36个月分别为56.1%、52.0%、44.6%。后续8周安全性与初始8周相似。

要点

  • 8周诱导无应答者延长至16周,52.2%达到临床应答。
  • 延迟应答者第12个月缓解率44.6%,第36个月仍为44.6%。
  • 延长诱导至16周的安全性与8周诱导相似。

核心结论

  • 多数患者经托法替布10 mg每日两次8周或16周诱导治疗达到临床应答。
  • 托法替布10 mg每日两次诱导治疗长达16周的安全性与8周诱导治疗相当。
  • 第36个月时多数延迟应答者处于缓解。

研究设计与样本

  • 基于2期剂量探索诱导试验、3项3期随机安慰剂对照试验(OCTAVE Induction 1和2;OCTAVE Sustain)及正在进行的开放标签长期扩展试验(OCTAVE Open)的评估。
  • 评估初始诱导8周未应答者接受托法替布10 mg每日两次延长诱导16周的短期和长期疗效与安全性。
  • 对延长诱导后达到临床应答者(延迟应答者)评估至OCTAVE Open第36个月的疗效与安全性。

主要发现

  • 诱导研究中托法替布10 mg每日两次治疗8周未达临床应答者中,52.2%经延长诱导后达到临床应答(延迟应答者)。
  • OCTAVE Open第12个月时,延迟应答者中70.3%维持临床应答、56.8%达到内镜改善、44.6%达到缓解。
  • 第36个月时,延迟应答者中56.1%维持临床应答、52.0%达到内镜改善、44.6%达到缓解。
  • 后续8周的安全性与初始8周相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib were demonstrated in a dose-ranging phase 2 induction trial, 3 phase 3 randomized, placebo-controlled trials (OCTAVE Induction 1 and 2; and OCTAVE Sustain), and an ongoing, open-label, long-term extension trial (OCTAVE Open) in patients with moderately to severely active UC. Here, we assessed short- and long-term efficacy and safety of extended induction (16 weeks) with tofacitinib 10 mg twice daily (BID) in patients who failed to respond to initial induction (8 weeks) treatment. METHODS: In patients who achieved a clinical response following extended induction (delayed responders), the efficacy and safety of tofacitinib were evaluated up to Month 36 of OCTAVE Open. RESULTS: 52.2% of patients who did not achieve clinical response to 8 weeks' treatment with tofacitinib 10 mg BID in the induction studies achieved a clinical response following extended induction (delayed responders). At Month 12 of OCTAVE Open, 70.3%, 56.8%, and 44.6% of delayed responders maintained clinical response and achieved endoscopic improvement and remission, respectively. Corresponding values at Month 36 were 56.1%, 52.0%, and 44.6%. The safety profile of the subsequent 8 weeks was similar to the initial 8 weeks. CONCLUSIONS: Overall, the majority of patients achieved a clinical response after 8 or 16 weeks' induction therapy with tofacitinib 10 mg BID. Tofacitinib 10 mg BID, administered as induction therapy for up to 16 weeks, had a comparable safety profile to 8 weeks' induction therapy. Most delayed responders at Month 36 were in remission. CLINICALTRIALS: gov: NCT00787202; NCT01465763; NCT01458951; and NCT01470612.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 33127596. doi:10.1016/j.cgh.2020.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。